Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Venous Thromboembolism 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Hemorrhage 1Carcinoma, Non-Small-Cell Lung 1

Interventions

ruxolitinib 24Cyclophosphamide 13Whole-Body Irradiation 10Tacrolimus 9Mycophenolic Acid 9fludarabine phosphate 8fludarabine 8Stem Cell Transplantation 8Specimen Handling 7Peripheral Blood Stem Cell Transplantation 7Azacitidine 6Busulfan 5navitoclax 4Sirolimus 4Melphalan 4Biopsy 4luspatercept 3fedratinib 3Methotrexate 3Injections 3Cyclosporine 3venetoclax 2selinexor 2parsaclisib 2letermovir 2itacitinib 2bomedemstat 2INCB057643 2INCB039110 2Hematopoietic Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × N(4)-oleylcytosine arabinoside × 1 year × Clear all
NCT05198960 2026-03-20

AVAJAK

University Hospital, Brest

Phase 3 Recruiting
1,308 enrolled
Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡